Skip to content
NewsBlazeIN – Lifestyle
Author:
Nasus Pharma, Ltd.
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
June 9, 2026
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
June 1, 2026
←
Previous Page
1
2